Drug Trial Radar · NCT07694557
A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection
Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Jul 29, 2026
Primary completion
Jul 1, 2028
Study completion Oct 1, 2028
Sponsor
- Lead sponsor
- Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection
Conditions
- Respiratory Syncytial Virus (RSV)
Interventions
YKYY025 groupDrug
intramuscular, a single intramuscular injection of the corresponding dose of YKYY025 for injection
YKYY025 Placebo groupDrug
intramuscular, a single intramuscular injection of the corresponding dose of YKYY025 Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events(AEs)Time frame: within 30 days after vaccination
- Serious adverse events (SAEs)Time frame: within 12 months after vaccination
- Heart rate in 12-lead electrocardiogram (ECG)Time frame: within 4 days after vaccination
- PR interval in 12-lead electrocardiogram (ECG)Time frame: within 4 days after vaccination
- RS duration in 12-lead electrocardiogram (ECG)Time frame: within 4 days after vaccination
- QT/QTC in 12-lead electrocardiogramTime frame: within 4 days after vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Anning First People's Hospital
Anning, Yunnan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.